US 8865873
Internalizing human monoclonal antibodies targeting prostate cancer cells in situ
granted A61KA61K2039/505A61K51/1072
Quick answer
US patent 8865873 (Internalizing human monoclonal antibodies targeting prostate cancer cells in situ) held by The Regents of the University of California expires Mon Oct 16 2034 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- The Regents of the University of California
- Grant date
- Tue Oct 21 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Oct 16 2034 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 9
- CPC classes
- A61K, A61K2039/505, A61K51/1072, A61P, A61P35/00